These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29759319)

  • 1. Mexiletine Prevents Recurrent Torsades de Pointes in Acquired Long QT Syndrome Refractory to Conventional Measures.
    Badri M; Patel A; Patel C; Liu G; Goldstein M; Robinson VM; Xue X; Yang L; Kowey PR; Yan GX
    JACC Clin Electrophysiol; 2015 Aug; 1(4):315-322. PubMed ID: 29759319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation.
    Kirchhof P; Franz MR; Bardai A; Wilde AM
    J Am Coll Cardiol; 2009 Jul; 54(2):143-9. PubMed ID: 19573731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias.
    Topilski I; Rogowski O; Rosso R; Justo D; Copperman Y; Glikson M; Belhassen B; Hochenberg M; Viskin S
    J Am Coll Cardiol; 2007 Jan; 49(3):320-8. PubMed ID: 17239713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mexiletine effectively prevented refractory Torsades de Pointes and ventricular fibrillation in a patient with congenital type 2 long QT syndrome.
    Nakashima R; Takase S; Kai K; Sakamoto K; Tsutsui H
    J Cardiovasc Electrophysiol; 2022 Jul; 33(7):1592-1595. PubMed ID: 35488741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study.
    Salem JE; Bretagne M; Lebrun-Vignes B; Waintraub X; Gandjbakhch E; Hidden-Lucet F; Gougis P; Bachelot A; Funck-Brentano C;
    Arch Cardiovasc Dis; 2019 Nov; 112(11):699-712. PubMed ID: 31477476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome.
    Darbar D; Kimbrough J; Jawaid A; McCray R; Ritchie MD; Roden DM
    J Am Coll Cardiol; 2008 Feb; 51(8):836-42. PubMed ID: 18294569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragmented QRS is associated with torsades de pointes in patients with acquired long QT syndrome.
    Haraoka K; Morita H; Saito Y; Toh N; Miyoshi T; Nishii N; Nagase S; Nakamura K; Kohno K; Kusano KF; Kawaguchi K; Ohe T; Ito H
    Heart Rhythm; 2010 Dec; 7(12):1808-14. PubMed ID: 20837161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrocardiographic Parameters Indicating Worse Evolution in Patients with Acquired Long QT Syndrome and Torsades de Pointes.
    Kukla P; Jastrzębski M; Fijorek K; Stec S; Bryniarski L; Czarnecka D; Baranchuk A
    Ann Noninvasive Electrocardiol; 2016 Nov; 21(6):572-579. PubMed ID: 27018992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternating Early Afterdepolarizations Underlying Bradycardia-Dependent Macroscopic T Wave and Discordant Mechanical Alternans.
    Qi D; Li W; Quan XQ; Gao Y; Wang J; Guo L; Zhao W; Liu T; Gao C; Yan GX
    Circ Arrhythm Electrophysiol; 2023 Jan; 16(1):e011453. PubMed ID: 36595630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful uses of magnesium sulfate for torsades de pointes in children with long QT syndrome.
    Hoshino K; Ogawa K; Hishitani T; Isobe T; Etoh Y
    Pediatr Int; 2006 Apr; 48(2):112-7. PubMed ID: 16635167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrocardiographic predictors of bradycardia-induced torsades de pointes in patients with acquired atrioventricular block.
    Cho MS; Nam GB; Kim YG; Hwang KW; Kim YR; Choi H; Kim SH; Rhee KS; Kim NJ; Kim JS; Kim J; Choi KJ; Kim YH
    Heart Rhythm; 2015 Mar; 12(3):498-505. PubMed ID: 25460857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
    Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
    Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of mexiletine in the management of long QT syndrome.
    Li G; Zhang L
    J Electrocardiol; 2018; 51(6):1061-1065. PubMed ID: 30497731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of late sodium current by mexiletine: a novel pharmotherapeutical approach in timothy syndrome.
    Gao Y; Xue X; Hu D; Liu W; Yuan Y; Sun H; Li L; Timothy KW; Zhang L; Li C; Yan GX
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):614-22. PubMed ID: 23580742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting torsade de pointes in acquired long QT syndrome: optimal identification of critical QT interval prolongation.
    Chiladakis J; Kalogeropoulos A; Zagkli F; Koutsogiannis N; Chouchoulis K; Alexopoulos D
    Cardiology; 2012; 122(1):3-11. PubMed ID: 22626988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Female gender as independent risk factor of torsades de pointes during acquired atrioventricular block.
    Chorin E; Hochstadt A; Viskin S; Rozovski U; Havakuk O; Baranchuk A; Enriquez A; Strasberg B; Guevara-Valdivia ME; Márquez MF; González-Pacheco H; Hasdemir C; Rosso R
    Heart Rhythm; 2017 Jan; 14(1):90-95. PubMed ID: 27650425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes.
    Lazzerini PE; Laghi-Pasini F; Bertolozzi I; Morozzi G; Lorenzini S; Simpatico A; Selvi E; Bacarelli MR; Finizola F; Vanni F; Lazaro D; Aromolaran A; El Sherif N; Boutjdir M; Capecchi PL
    Heart; 2017 Nov; 103(22):1821-1829. PubMed ID: 28490617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives.
    Kannankeril PJ; Roden DM; Norris KJ; Whalen SP; George AL; Murray KT
    Heart Rhythm; 2005 Feb; 2(2):134-40. PubMed ID: 15851285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of torsades de pointes in older patients with drug-associated long QT syndrome: a case-control study.
    Goutelle S; Sidolle E; Ducher M; Caron J; Timour Q; Nony P; Gouraud A
    Drugs Aging; 2014 Aug; 31(8):601-9. PubMed ID: 24923384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.